A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry

Basit Öğe Kaydı
dc.authoridBirlik, Ahmet Merih/0000-0001-5118-9307
dc.authoridTUFAN, ABDURRAHMAN/0000-0001-6244-9362
dc.authoridYazıcı, Ayten/0000-0003-2167-4509
dc.authoridSari, Ismail/0000-0001-7737-4180
dc.authoridYıldız, Fatih/0000-0003-3628-8870;
dc.authorwosidBirlik, Ahmet Merih/AIA-2552-2022
dc.authorwosidÖztürk, Mehmet/JFJ-3399-2023
dc.authorwosidTUFAN, ABDURRAHMAN/A-7613-2016
dc.authorwosiderten, sukran/IZE-6133-2023
dc.authorwosidKOCA, SULEYMAN SERDAR/HJY-2666-2023
dc.authorwosidSolmaz, Dilek/B-1448-2016
dc.authorwosidCefle, Ayse/AAT-3653-2020
dc.contributor.authorOnen, Fatos
dc.contributor.authorCan, Gercek
dc.contributor.authorCapar, Sedat
dc.contributor.authorDalkilic, Ediz
dc.contributor.authorPehlivan, Yavuz
dc.contributor.authorSenel, Soner
dc.contributor.authorAkar, Servet
dc.date.accessioned2024-08-04T20:10:35Z
dc.date.available2024-08-04T20:10:35Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018. Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treatments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens. Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a conventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31. Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey.en_US
dc.identifier.doi10.5152/eurjrheum.2022.21060
dc.identifier.endpage87en_US
dc.identifier.issn2147-9720
dc.identifier.issn2148-4279
dc.identifier.issue2en_US
dc.identifier.pmid35546332en_US
dc.identifier.startpage82en_US
dc.identifier.trdizinid533376en_US
dc.identifier.urihttps://doi.org/10.5152/eurjrheum.2022.21060
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/533376
dc.identifier.urihttps://hdl.handle.net/11616/92882
dc.identifier.volume9en_US
dc.identifier.wosWOS:000841493100004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofEuropean Journal of Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiologic registryen_US
dc.subjectrheumatic diseaseen_US
dc.subjectTurkeyen_US
dc.titleA real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu